Stockscreener 앱 받기
1.68
6.15%
-0.11
시간 외 거래:
1.66
-0.02
-1.19%
전일 마감가:
$1.79
열려 있는:
$1.77
하루 거래량:
1.69M
Relative Volume:
0.16
시가총액:
$7.20M
수익:
$960.60K
순이익/손실:
$-7.10M
주가수익비율:
-0.2222
EPS:
-7.56
순현금흐름:
$-8.00M
1주 성능:
+21.74%
1개월 성능:
-39.57%
6개월 성능:
-11.11%
1년 성능:
-57.89%
1일 변동 폭
$1.61
$1.7975
1주일 범위
$1.325
$1.97
52주 변동 폭
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
SNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.68 | 14.98M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix Inc.’s volatility index tracking explained2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Why analysts raise outlook for Soligenix Inc. (DOA0) stock2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Soligenix (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL - The Globe and Mail
Is Soligenix Inc. (DOA) stock overpriced at current multiplesWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
What machine learning models say about Soligenix Inc.Weekly Investment Report & Entry Point Confirmation Signals - newser.com
Soligenix Inc. stock retracement – recovery analysisJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Applying chart zones and confluence areas to Soligenix Inc.Portfolio Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
Soligenix Expands European Advisory Board to Advance CTCL Treatment Development - citybuzz
Does Soligenix Inc. show high probability of reboundShare Buyback & Growth Focused Stock Pick Reports - newser.com
Will Soligenix Inc. stock recover after recent dropJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
How to manage a losing position in Soligenix Inc.July 2025 Momentum & Short-Term High Return Strategies - newser.com
Soligenix (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL - Digital Journal
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates - MarketScreener
EV PD-L1 Decreases in 3 Patients: Aethlon Medical Hemopurifier Shows Early EV, miRNA and T‑cell Changes - Stock Titan
Soligenix Reports Positive Safety Review in Phase 3 CTCL Treatment Trial - citybuzz
Soligenix Stock (SNGX) Opinions on Phase 3 HyBryte™ Safety Milestone - Quiver Quantitative
Soligenix’s Strategic Moves: A Bright Future Ahead? - timothysykes.com
Soligenix shares surge after safety milestone in Phase 3 CTCL trial - MSN
Soligenix stock soars after DMC confirms safety in Phase 3 CTCL study - Investing.com
Soligenix (SNGX) Advances Phase 3 CTCL Study with Positive Safet - GuruFocus
Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial - TipRanks
Soligenix achieves important safety milestone in its confirmatory phase 3 Clinical Trial of HyBryte(TM) for the treatment of cutaneous T-cell lymphoma - MarketScreener
Soligenix reports safety milestone in phase 3 CTCL treatment trial By Investing.com - Investing.com Canada
Soligenix reports safety milestone in phase 3 CTCL treatment trial - Investing.com
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
What analysts say about Soligenix Inc DOA stockEarnings Per Share Trends & Learn to Pick Stocks in Under 10 Minutes - earlytimes.in
Has Soligenix Inc. formed a bullish divergence2025 Retail Activity & Verified Entry Point Signals - newser.com
Regression analysis insights on Soligenix Inc. performance2025 Trade Ideas & Weekly Momentum Picks - newser.com
Should you hold or exit Soligenix Inc. nowBear Alert & Verified Swing Trading Watchlists - newser.com
Using AI based signals to follow Soligenix Inc.Weekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Why Soligenix Inc. (DOA0) stock is trending on social media2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Statistical indicators supporting Soligenix Inc.’s strengthWeekly Stock Report & Low Volatility Stock Recommendations - newser.com
Using economic indicators to assess Soligenix Inc. potentialTrade Exit Report & Consistent Profit Trading Strategies - newser.com
Is Soligenix Inc. (DOA) stock a momentum leaderQuarterly Market Review & Daily Price Action Insights - newser.com
Is Soligenix Inc. stock ready for a breakoutEarnings Growth Summary & Consistent Return Strategy Ideas - newser.com
Insider Buying: Christopher Schaber Acquires Shares of Soligenix Inc (SNGX) - GuruFocus
Can trapped investors hope for a rebound in Soligenix Inc.Day Trade & Daily Profit Focused Screening - newser.com
Why Soligenix Inc. (DOA0) stock remains top ratedJuly 2025 Patterns & Smart Swing Trading Techniques - newser.com
What downside risks could hit Soligenix Inc. (DOA0) stock2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Will Soligenix Inc. stock deliver long term returnsSell Signal & Community Consensus Trade Alerts - newser.com
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):